ETNB

89bio to Present at the Oppenheimer 31st Annual Healthcare Conference

89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference

89bio: NASH Drug Developer With Differentiated Profile

89bio to Participate in the H.C. Wainwright BioConnect 2021 Conference

89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at AASLD's The Liver Meeting® 2020

89bio Reports Third Quarter 2020 Financial Results and Provides Corporate Update

89bio (ETNB) Investor Presentation - Slideshow